Abstract. The world is facing one of the major outbreaks of viral infection of the modern history, however, as vaccine development workflow is still tedious and can not control the infection spreading, researchers are turning to passive immunization as a good and quick alternative to treat and contain the spreading. Within passive immunization domain, raising specific immunoglobulin (Ig)Y against acute respiratory tract infection has been developing for more than 20 years. Far from being an obsolete chapter we will revise the IgY-technology as a new frontier for research and clinic. A wide range of IgY applications has been effectively confirmed in both human and animal health. The molecular particularities of IgY give them functional advantages recommending them as good candidates in this endeavor. Obtaining specific IgY is sustained by reliable and nature friendly methodology as an alternative for mammalian antibodies. The aria of application is continuously enlarging from bacterial and viral infections to tumor biology. Specific anti-viral IgY were previously tested in several designs, thus its worth pointing out that in the actual COVID-19 pandemic context, respiratory infections need an enlarged arsenal of therapeutic approaches and clearly the roles of IgY should be exploited in depth.

1. Introduction

Respiratory tract infections (RTI) are extremely common and in developed countries, RTI account for over 20% of all medical consultations (1). In children, the figures are even higher. Worldwide, every year, over 1 million children and infants under 5 years die from acute respiratory infections (2), this disease represents in developing countries the cause of death of 30% of children under five years (3,4). When RTI have an increased frequency, over 60% of the cases have a primary immunodeficiency in humoral immunity. A recent study has shown that deficiencies in immunoglobulin (Ig) synthesis and secretion are proven in abnormal levels of IgG, IgA and IgM (5). Not only Igs are affected, but also other immune molecules. In children diagnosed with RTI decreased levels of proinflammatory cytokines were identified, mainly interferon (IFN)-γ (6). IFN-stimulated genes (ISGs) are highly involved in the antiviral immune response (7).

In bacterial infection multidrug-resistant (MDR) processes are involved in the difficult-to-treat pathogens (8-10), but in viral infections this process has just a collateral importance because a substantial proportion of RTI are actually acute viral infections. The treatment of these infections relies on antivirals and on relieving disease symptoms. However, similarly to bacterial infections, antiviral agents would conserve viral proteins, that will induce a selective pressure on the viral particle, leading to development of antiviral resistance (11,12).

As the best ‘treatment’ is prevention, in viral infections vaccination is the best approach, but the pace of vaccine development is slow and it has to overcome various hurdles, e.g., antigenic variations, low efficacy, short-term immune responses. As we are now faced with one of the major outbreaks of viral infection of the modern history, vaccine development workflow can not control the infection spreading (13). Therefore, novel approaches are tested and designed. One of these novel approaches is passive immunization (14) where mainly polyclonal antibodies derived from several sources
(e.g., sera of immunized animals, immunized humans, convalescing patients) can be used (15,16). In this case also the use of polyclonal antibodies has some hurdles such as standardization and patient safety. Monoclonal antibodies (mAbs) is the best choice but their production costs are still very high, as an example the high costs of monoclonal antibodies used in melanoma therapies (17). The costs increase further in respiratory infection because there are viral escape mutants that would need additional mAbs (18). Therefore in this complex picture of immunity in viral infection an interesting approach has risen in recent years - the use of specific IgY. IgY is produced by birds, reptiles and amphibians with a function similar to that of mammalian IgGs (19). IgYs are circulating in the sera as IgGs, but in addition they accumulate 100 times more concentrated in the egg yolk and are passed to the developing embryo (20).

IgY antibodies extracted from hen eggs have been used in bacterial (21) and viral infections therapy (22). It has some favorable characteristics: it is well tolerated due to human diet, it can be used in individuals who are allergic to eggs because the purified IgY is depleted of egg albumin (23), it has a good tolerability. Moreover, the systemic administration has shown the capability of specific IgY raised against viruses to protect against actual diseases. For example, in pig model IgY protected against Rotavirus infection (24). Systemic and local administration of IgY in mammals have shown that an anti-IgY antibody response was generated, mainly consisting of the IgG subclass. These reports show that IgY is antigenic but this antibody molecule cannot bind to mammalian Fc receptors, so adverse effects on this route are minimal (25).

More than 20 years ago it was shown that in mouse model administration of IgY, purified or not, did not induce an IgE response, hence no allergic response (26) and due to the fact that IgY does not link to the human complement system or Fc receptors, additional inflammation upon administration is minimal (27). IgY action is to bind to the bacteria or virus, and facilitate the elimination of the agent through the gut preventing bacterial or viral replication and spread (28).

Passive immunization with IgY can be given in humans with active infection as they develop a rapid response. Moreover, immature infants or immune-suppressed patients can also benefit from this passive immunization (29,30). IgY has a high content of sialic acid (31), with increased half-life (32) that suggests IgY to have a longer circulating half-life, and hence increased anti-pathogen action and increased efficacy against infections (33).

We aim to highlight in this review that in the quest to find quick and effective anti-viral therapies, specific IgY can be another possibility to fight against viral RTI.

2. IgY an established immune-fighter - is there something new on its (bio) applications?

An antigen attack upon host is followed by Igs or antibodies production in humans, process sustained by plasma cells developing thus the humoral immunity (34). Antibodies engage in the fight against the antigen by an array of mechanisms: neutralization, fixation of pathogen, complement activation or acting like receptors on B cell surface (35). Igs have interspecies differences regarding their structural particularities or classes, thus the term IgY comes from egg yolk where this Ig type is produced for assuring immunity in the hen progeny. IgY represents the functional equivalent of human IgG (29). In the last decade, IgY has gained scientific attention due to its distinctive biological actions largely emerged from its structural particularities (36).

Currently there are several commercial applications where Igs are fully explored in diagnostic and therapy monitoring assays.

**Fighting against bacterial infections.** Immunization of avian with specific bacterial antigens such as *Salmonella sp.* would provide a specific IgY against the inductor antigen. Moreover, due its high stability and structural unique features IgY has been applied successfully in diagnostic, prophylactic and therapeutic purposes as well as immunochemical reagents (34).

In addition to chicken models, there are other hands-on and inexpensive models such as the quail model where production of specific IgYs against *Salmonella sp.* has been recently reported. These quail anti-*Salmonella sp.* IgYs exhibit a high specificity to their matching immunogens, having the potential to eradicate enterobacterial pathogens. In addition, the oral ingestion of IgYs represent an efficient alternative for annihilation of gastrointestinal pathogens as *Salmonella typhimurium* and *Salmonella enteritidis*, bacterial species that raise major concern in health and food industry (37).

IgYs has also been proposed as a strategy for combating infections caused by *Pseudomonas aeruginosa* known as a common nosocomial pathogen having antibiotic resistance and a frequent infection in acute pneumonia and severely burned patients. A protein called PerV is a vital part of killing machinery represented by the type III secretion system of *P. aeruginosa* and therefore PcrV is viewed as a target for neutralizing this infectious agent. Thus, recently recombinant PcrV was used for raising specific IgYs. These antibodies displayed a protective effect in both acute pneumonia and burn wound models and moreover IgY anti-PcrV has augmented opsonization capacity and bacterial killing activity of host cells (38). In fact the augmentation of phagocytic killing via IgY was previously explored in an *in vitro* study targeting *P. aeruginosa* infection in cystic fibrosis (CF) patients. IgY against *P. aeruginosa* fulfill their function by opsonizing the pathogen and thus enhancing the neutrophils respiratory burst while further enabling bacterial killing. It was suggested that prophylaxis with anti-*P. aeruginosa* IgY could lift the innate immunity of CF patients aiding host neutrophils to rapidly clear the bacterial agent (39).

In CF the principal contributor of pulmonary failure is the chronic infection with *P. aeruginosa* biofilm, which constantly attracts and activates neutrophils sustaining the continuous inflammation. It is suggested that IgY favors bacteria to form aggregates and increase their hydrophobicity enhancing bacterial killing by neutrophils via phagocytosis (40).

Passive immunization with IgY anti-*P. aeruginosa* could reduce the initial airway settlement with *P. aeruginosa* in CF patients. Thus in a Balb/c murine *P. aeruginosa* pneumonia model administration of specific IgY significantly reduced the bacterial load at 24 h after infection along with alleviating the clinical symptoms; in addition an inflammatory cytokine pattern was noted revealing the lung inflammation decrease
suggested that immune-prophylaxis with anti-\textit{P. aeruginosa} IgY may also function as an adjuvant to antibiotics in lowering primary colonization of lungs (21). In parasitic diseases the possible role of IgY in early diagnosis and therapeutics has been tackled by attempting to obtain polyclonal IgY against parasitic antigens suitable for immunotherapeutic purposes. Although further studies in animal models are indispensable and obtaining a monoclonal IgY anti-parasitic antigens are envisaged, it became obvious that IgY could stand for immunoassay designing also in parasitology area (41).

In immunodiagnostics, IgY is an excellent tool in assays involving mammalian sera, due to the discriminative properties of IgY compared to mammalian IgG. IgY has immunological properties which makes it very distinct from mammalian IgG but at the same time very affordable for a plenty of immunological approaches. Foremost, by lacking the hinge region, IgY is less structurally flexible than IgG and retains a different protein content, these structural differences sustaining the differences in immunological behavior (42). IgY has poor cross-reactivity to mammalian IgG, does not activate the complement system similar to IgM/IgG and lacks the reactivity with mammalian Fc receptor (43).

However, there are still incomplete data regarding the three-dimensional structure of Fc-IgY raising the question whether IgY shares a conformational status similar to IgM and IgE whose Fc regions are significantly flexible. However, the evolutionary distance between mammals and birds made possible the feasible generation of IgY against conserved mammal proteins. Thus, the molecular particularities of IgY raised several functional advantages recommending IgY as a versatile tool in biotechnological research, diagnostics and therapeutics (29). One very practical utility is that IgY can be used to generate a specific antibody when an antigen comes in small amounts and additionally is low immunogenic in mammals host (44).

IgY can be generated at low-costs in considerable amounts through an ecologically friendly approach because it is produced in egg yolk so no additional procedures on animals are needed. There are several IgY isolation methods available, mostly based on precipitation from egg extracts using ammonium sulfate or polyethylene glycol although protein impurities still remains in the sample of interest, in addition to time consuming and complexity required (45,46). Chromatographic methods have become very popular in recent years because this methodology generates highly active pure products useful for biomedical applications. A study published in 2020 reports IgY fragment separations by ion exchange column using DEAE-Sepharose leading to Fab and Fc fractions of high purity (88.7 and 90.1%, namely) and intact activity rendering them easily used for medical purposes (47).

Usually, antibodies and/or their active fragments produced in mammals are engaged in diagnostic tests. However, due to animal welfare concerns, technical advantages and the high cost of production, alternatives to the production of antibodies in mammals have been investigated (48).

A constant goal for all current approaches involving IgY applications is to continuously optimize the production and purification of IgY antibodies from egg yolk to achieve high quantities and high active products for research and commercial use.

The most exploited immunoassay format with IgY remains the ELISA platform. In research as well as in clinic, one of the most effective and reliable method for rapid detection remains ELISA which is a versatile, flexible and sensitive method helpful in monitoring various pathologies including infectious diseases. Although IgG is the ‘weapon of choice’ in designing such detection formats, in recent years IgY started to replace IgG because this molecule could be easily obtained, through a non-invasive way (basically extracted and purified from egg yolk of chickens immunized with recombinant proteins of interest), in adequate amounts and at lower costs than IgG.

IgY-based ELISA protocols retain all the features related to steps, reagents and applications of classic ELISA formats as IgY molecule can be enzymatically labeled (e.g., with horseradish peroxidase) and further applied in a wide range of immunoassay assessments such as bacterial toxins (49) or tumor antigen detection for cancer diagnosis (50,51).

It is truly noticeable how versatile the use of IgY could be related to area of application, from viruses and bacteria to tumor antigens detection and quantification (42). Thus, diagnosis of cholera is somewhat an intricate attempt. Therefore, a recent study proposed IgY for targeting two proteins contained by the outer membrane of \textit{V. cholerae} (protein W and cytotoxin B). The study proposed two sensitive and specific sandwich ELISA formats, with no cross-reactivity with other bacteria. It was suggested that these IgY based ELISAs could constitute a rapid and specific detection tool for assessing \textit{V. cholerae} in different biological samples (52).

The use of IgY instead of mouse monoclonal IgG has the advantage of limiting the risk of false positive results as well as the reduced costs of the test. For example, an IgY-based sandwich ELISA was developed to quantify the total PSA level in human serum as an alternative to commercially available \textit{in vitro} diagnosis tests (53).

Taking into account the latest concerns raised by respiratory infections of viral origin IgY might act as a very promising detection agent in this area. Thus, recent studies in swine model suggest that IgY molecule could bind specifically to viral nucleoprotein of influenza virus, which is known for exerting a key role in viral replication and therefore emphasizing the IgY effectiveness for influenza virus diagnosis (48,54).

\textit{Is there some spare room for other methodologies regarding IgY characterization in the last decade?} As already mentioned, IgY purification is currently achieved by conventional precipitation methods with ammonium sulphate or PEG and by chromatographic procedures. Sequential precipitation with 31% ammonium sulfate and 12% polyethylene glycol (PEG) produces IgY antibodies with above 95% purity without any loss in immunoreactivity (55).

Additional procedures of purification could be added to the separation methodologies, such as high-resolution chromatography accomplished for instance by multi-column systems such as NGC scout Bio-Rad system. Especially, but not restricted to mAbs, this system provides certain advantages over conventional chromatographic columns in terms of automatization, reproducibility and accessibility. During the process of obtaining biomolecules intended for biomedical application, high purity and intact functionality are the first considerations. Moreover a multi-column automated system
could resolve several steps of purification in a single run, such as separation by affinity purification of a particular compound from original matrix, size exclusion to resolve aggregates and finally obtaining the product of interest with undamaged structure and function (56). By choosing the appropriate column the compound is loaded, purified and analyzed in a continuous run. High purification is further explored for designing platforms in which pathogens could be discriminated or when ELISA type platform are constructed intended for research or diagnosis.

An example of analyzing an IgY extract isolated from hen egg yolk by the Romanian Company Romvac S.A. using NGC scout Bio-Rad system is presented in Fig. 1.

3. Passive immunization in infectious diseases

Passive immunization as general process. Passive immunization refers to administering already mature antibodies (Igs) in an attempt to rapidly overcome an infectious disease (57). Passive immunity can represent a natural phenomenon and/or can be artificially induced (58).

The natural passive immunity consists of maternal antibodies that are transferred to the offspring inducing protection before the offspring's self-immunity is built up. In birds, passive immunity is sustained by the IgY from the egg yolk which enters into the developing embryo (59,60) and hence sustaining the first 2 weeks immunity in chickens, at the time when they start to build up their own immunity (61). In mammals passive immunity is sustained by maternal antibodies that are transferred to the fetus through the placenta, in humans this process is active especially during the last 3 months of pregnancy. Then the passive immunity is sustained by milk that also contains antibodies (62).

Artificially induced passive immunity is sustained by transferring antibodies by systemic, intravenous, or oral routes. Passive immunity is limited in time, thus, to sustain this immunity, preformed antibodies should be re-introduced (63).

A low-cost and rapid technology to obtain large scale passive immunity antibodies are IgY from egg yolk via hyperimmunization of chickens. Briefly this process involves hen immunization with specific antigens with a specific time schedule so that specific IgYs accumulate in the egg yolks. Afterwards, these IgY are extracted (55,64). Passive immunization has a history of more than 100 years and has been used in both humans and animals (67,68). Over 20 years ago, one of the first reports was published showing that intranasal antibody prophylaxis was successful against viral respiratory infections in animal models [e.g., against respiratory syncytial virus (RSV), influenza virus, Sendai virus], and entered human clinical trials for influenza A and B viruses, Coxsackie virus, and rhinoviruses (67). Since then only non-viral IgY applications have been published such as oral administration of IgY preventing or treating diseases induced by Streptococcus mutans (dental carries), E. coli-diarrhea, gastritis (H. pylori), periodontitis (P. gingivalis) and oral candidiasis (C. albicans) infant rotavirus diarrhea (23). Rotavirus-induced diarrhea containing IgY (Rotamix IgY) was efficient in pediatric patients diagnosed with non-cholera enteric pathogen and was proven as a good adjuvant for the management of acute diarrhea (68). Therefore, IgY raised for specific viral respiratory infections should enter the spotlight again.
**IgY in passive immunization.** IgY utilization in passive immunization has several advantages. Obtaining IgY from birds is ecologically friendly, the extract does not induce specific resistance and/or side effects and due to their specificity would not affect beneficial microbial population of the host.

Finally, if used as therapy in poultry and livestock IgY does not stay in the meat that is destined to human consumption as antibiotics do (69).

Using specific IgY in passive immunization is not age restricted, it can be applied to a wide range of ages, to a wide array of individuals characterized by pathophysiological conditions, e.g., women in special conditions like pregnancy and/or immunodeficient patients.

IgY antibodies are naturally non-toxic and when lyophilized they can be stored in regular 4˚C or even at room temperature without losing their efficacy. Production costs are much lower when compared to standard mAbs and/or vaccines. Then storing can be done for months and transportation is thus facilitated in comparison to other biologicals (70). If not extracted the composition of IgY stored in eggs remains unchanged for at least 1 year at 4˚C (71). The product, IgY is collected from eggs and, therefore, does not impede the animal welfare.

From a molecular point of view, IgY has increased binding avidity for the antigens that generated them in comparison to mammalian IgG (72). Due to the evolutionary distance between mammals and birds IgY can be produced more easily against conserved mammalian molecules than IgG antibodies (73). For IgY generation a lower antigen load is necessary to induce the specific immune response (69).

For mass production, as the production of eggs for human consumption is already carried out on an industrial scale the production of eggs containing specific IgY already has its industrial backbone (74). One chicken can produce specific IgY of approximately 22 g/year (45).

### 4. Learning from severe acute respiratory syndrome

Almost 20 years ago, coronaviruses (CoVs) were known to cause disease only in vertebrates but then, the severe acute respiratory syndrome (SARS)-CoV outbreak in China showed the medical world that nature still has unknown paths (75). The disease spread rapidly worldwide, causing under 10,000 infections with a 10% mortality rate (76,77). Through the SARS epidemic in China, passive immunization that used sera from recovered SARS patients offered positive results (78). IgY preparations were obtained with anti-SARS coronavirus action after isolation from egg yolk obtained from pathogen-free chickens immunized with SARS coronavirus antigen (78). It was reported that the obtained IgY had both high purity and biological activity. In cells model, the obtained IgY neutralized the SARS coronavirus. The preparation was stable upon lyophilization, that gave the product good manufacturing qualities (78). Anti-SARS IgY preparations were obtained with anti-SARS coronavirus action after isolation from egg yolk obtained from pathogen-free chickens immunized with SARS coronavirus antigen (78). It was reported that the obtained IgY had both high purity and biological activity. In cells model, the obtained IgY neutralized the SARS coronavirus. The preparation was stable upon lyophilization, that gave the product good manufacturing qualities (78). Anti-SARS IgY produced upon this procedure is a good candidate for anti-SARS-CoV therapy. The authors stated that in case of an outbreak, a rapid intervention can be sustained by production of IgY antibodies. The production of an IgY antibody takes 1.5 months from hens vaccination to IgY production, so until a vaccination for an eventual outbreak is put in use, this rapid response can fulfill an urgent medical

| Pathogen                  | Model type                | Effect                                                                 |
|---------------------------|---------------------------|------------------------------------------------------------------------|
| Pandemic influenza virus A/H1N1 | MDCK cells infected with pandemic virus | Neutralizing of viral infectivity in the cells (82)                     |
| Influenza B virus         | MDCK cells               | Neutralizing of viral infectivity in the cells (83)                     |
| Influenza A virus         | Hens immunized with H1N1 virus | Reducing viral replication in the lungs (84)                             |
| Viruses H1N1, H3N2, and H5N1 strain | Hens immunized with whole inactivated H1N1, H3N2, and H5N1 virus | Neutralizing of viruses in MDCK cells with H1N1 and H3N2 (85)           |
| SARS                      | SPF chickens immunized with inactivated SARS coronavirus | 100% protection against challenge with H5N1 and A/Puerto Rico 8/34 H1N1 in BALB/c and C.B-17 mice |
| BRSV related to human syncytial virus | VERO E6 cells | Neutralizing SARS coronavirus in the cells (78) |
| IgY, immunoglobulin Y      | MDCK cells infected with A59098 BRSV strain | Neutralizing of viruses in MDCK cells (78)                              |
need. Moreover even when a proper vaccination is established, using this type of passive immunizations can significantly increase the control of the epidemic (78).

In 2007 a post-SARS outburst paper has shown that there is SARS-CoV viral reservoir that is actually a biological bomb waiting to explode (79) and now, after 15 years we are facing the biggest pandemic since the Spanish Flu in 1918. The medical world is ‘fast forwarding’ research and translating research results to bedside. In this race, information changes almost in each hour. At present time, in the race to obtaining quickly a vaccine there are 44 products with 2 in clinical trial phase I (80), but these data will be obsolete in the forthcoming month. Nevertheless, until vaccination enters the application stages there are several steps and phases to be taken. Therefore, probably by the end of 2020 there will be the most accelerated approved vaccine. Alternative methods to overcome the outbreak and to therapeutically sustain infected patients are urgently needed. Passive immunization with plasma from recovered patients was already approved in USA (81). In this picture of passive immunization therapy IgY can have a future role.

Table I summarizes the main studies that used anti-viral respiratory infection IgY emphasizing on the experimental models, whether cellular or animal models.

5. Conclusions and future perspectives

Menacing viruses causing pandemics such as COVID-19 claim imperative future measures shaped in therapeutics and novel vaccines. Large-scale and coordinated effort are needed to minimize the impact of these threats on human health (87,88). Joining these efforts, additional therapeutics open the perspective of using passive immunization with IgY on large scale as adjuvant therapy in viral respiratory infection. This endeavor should focus on aspects of increased production, improved hen immunization protocols, improved IgY extraction and increased antibody yield. Another point to be taken into consideration in the future is that chicken IgY have good monoclonality, therefore are more specific and have higher affinity in comparison to the ones obtained from immunizing mammals (89). As compared to IgGs, obtaining genetically engineered single chain fragment variable for IgY (IgY-scFv) is easier as these fragments were already implemented in diagnostics and therapy (29,90).

Therefore, using specific IgY in viral respiratory infections have good premise and can be expanded to other infectious diseases.

In conclusion, far from being an obsolete chapter in immunodiagnostics, the IgY-technology is revised as a new frontier for research and clinic as already a wide range of IgY applications has been effectively confirmed in both human and animal health. The molecular particularities of IgY give them functional advantages recommending IgY as a versatile tool in biotechnological research, diagnostics and therapeutics. The main advantage is that IgY methodology is a reliable and nature friendly alternative for obtaining mammalian antibodies, as it is a non-invasive procedure. The area of application is continuously enlarging from bacterial and viral infections to tumor biology. Specific anti-viral IgY has already been tested in several designs, thus it is worth pointing out that in the actual COVID-19 pandemic context, respiratory infections need an enlarged arsenal of therapeutic approaches and definitely IgY roles should be exploited in depth.

Acknowledgements

Authors would like to thank Dr Alexandra Livescu and Dr Ovidiu Geicu (Dialab Solutions) for their invaluable technical assistance in NGC scout Bio-Rad system separations.

Funding

This study was supported by IntelBiomed project, SMIS code 105631, ID: P_40_197, Grant No. 52/2016.

Availability of data and materials

The information analyzed during the current study is available from the corresponding author on reasonable request.

Authors' contributions

All authors substantially contributed to the writing and revision of the work and read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

DAS is the Editor-in-Chief for the journal, but had no personal involvement in the reviewing process, or any influence in terms of adjudicating on the final decision, for this article. The other authors declare that they have no competing interests.

References

1. Bryce J, Boschi-Pinto C, Shibuya K and Black RE; WHO Child Health Epidemiology Reference Group: WHO estimates of the causes of death in children. Lancet 365: 1147-1152, 2005.
2. Qazi S, Aboubaker S, MacLean R, Fontaine O, Mantel C, Goodman T, Young M, Henderson P and Cherian T: Ending preventable child deaths from pneumonia and diarrhoea by 2025. Development of the integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea. Arch Dis Child 100 (Suppl 1): S23-S28, 2015.
3. Ujwala F and Ezeneuz C: Risk factors for acute respiratory tract infections in under-five children in enugu Southeast Nigeria. Ann Med Health Sci Res 4: 95-99, 2014.
4. Munteanu AN, Surcel M, Constantin C and Neagu M: Syncytial virus respiratory infections in children - immunological aspects. Rev Biol Biomed Sci 2: 29-39, 2019.
5. Pasternak G, Lewandowicz-Uzynska A and Pentoś K: Disorders of humoral immunity in children with IgG subclass deficiency and recurrent respiratory infections. Adv Exp Med Biol 1108: 99-106, 2018.
6. Ivanova ON, Argunova EF, Alekseev SN, Ystugina TV, Varfolomeev AR, Troip IP, Kononova IV and Egorova VE: Adaptive mechanisms of the immune system in children in far north. Wiad Lek 68: 534-536, 2015.
7. Liu Z, Qin Q, Wu C, Li H, Shou J, Yang Y, Gu M, Ma C, Lin W, Zou Y, et al: Downregulated NDR1 protein kinase inhibits innate immune response by initiating an mTORa6am-STAT1 feedback loop. Nat Commun 9: 2789, 2018.

8. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Brady C, Guill M, Lahiri T, Lubsch L, Matsuji J, Oermann CM, Ratjen F, et al: Cystic Fibrosis Foundation Pulmonary Clinical Practice Guidelines Committee: Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Am Ann Thorac Soc 11: 1640-1650, 2014.

9. Mogayzel PJ Jr, Naureckas ET, Robinson KA, Mueller G, Hadjiliadis D, Hoag JF, Lubsch L, Hazle L, Sabadosa K and Marshall B: Pulmonary Clinical Practice Guidelines Committee: Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 187: 680-689, 2013.

10. Pasteur MC, Bilton D and Hill AT; British Thoracic Society Bronchiectasis non-CF Guideline Group: British Thoracic Society guideline for non-CF bronchiectasis. Thorax 65 (Suppl 1): i-158, 2010.

11. McCaskill JL, Ressel S, Alber A, Redford J, Power UF, Schwarze J, Dutia BM and Buck AH: Broad-spectrum inhibition of respiratory virus infection by MicroRNA mimics targeting p38 MAPK signaling. Mol Ther Nucleic Acids 7: 256-266, 2017.

12. Ge X, Xu W: Evaluation of coronavirus disease case-fatality risk in real time. Emerg Infect Dis: Apr 21, 2020 (Epub ahead of print).

13. Corti D, Passini N, Lanzavecchia A and Zambon M: Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome. J Infect Public Health 9: 231-235, 2016.

14. Sparrow E, Frieide M, Sheikh M and Torvaldsen S: Therapeutic antibodies for infectious diseases. Bull World Health Organ 95: 235-237, 2017.

15. Graham BS and Ambrosino DM: History of passive antibody administration for prevention and treatment of infectious diseases.Curr Opin HIV AIDS 10: 129-134, 2015.

16. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA: Mar 27, 2020 (Epub ahead of print).

17. Anucerceanu R and Neagu M: Immune based therapy for melanoma. Indian J Med Res 143: 135-144, 2016.

18. Casadevall A, Dadachova E and Pirofski LA: Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2: 695-703, 2004.

19. Warr GW, Mager KE and Higgins DA: IgY: Clues to the origins and evolution of modern antibodies. Immunol Today 16: 392-398, 1995.

20. Sparrow E, Frieide M, Sheikh M and Torvaldsen S: Therapeutic antibodies for infectious diseases. Bull World Health Organ 95: 235-237, 2017.

21. Graham BS and Ambrosino DM: History of passive antibody administration for prevention and treatment of infectious diseases. Curr Opin HIV AIDS 10: 129-134, 2015.

22. Chen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L, et al: Treatment of 5 critically ill patients with COVID-19 with convalescent plasma. JAMA: Mar 27, 2020 (Epub ahead of print).

23. Anucerceanu R and Neagu M: Immune based therapy for melanoma. Indian J Med Res 143: 135-144, 2016.

24. Casadevall A, Dadachova E and Pirofski LA: Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2: 695-703, 2004.

25. Warr GW, Mager KE and Higgins DA: IgY: Clues to the origins and evolution of modern antibodies. Immunol Today 16: 392-398, 1995.

26. Carlander D, Stålberg J and Larsson A: Chicken antibodies: A key in the battle against infectious diseases. Curr Opin HIV AIDS 10: 129-134, 2015.

27. Thirumalai D, Visaga Ambi S, Vieira-Pires RS, Xiaoying Z, Sekaran S and Krishnan U: Chicken egg yolk antibody (IgY) as an alternative to mammalian antibodies. Indian J Med Res 158: 293-303, 2015.

28. Xu Y, Li X, Jin L, Zhen Y, Lu Y, Li S, You J and Wang L: Application of chicken egg yolk immunoglobulins in the control of terrestrial and aquatic animal diseases: A review. Biotechnol Innov 5: 860-868, 2011.

29. Zhang X, Calvert RA, Sutton BJ and Doré KA: IgY: A key isotype in antibody evolution. Bio Rev Camb Philos Soc 92: 2144-2156, 2017.

30. Muller S, Schubert A, Zajac J, Dyck T and Oelkrug C: IgY antibodies in human nutrition for disease prevention. Nutr J 14: 109, 2015.

31. Gilgumn S, Milian Martín S, Wormald MR, Zapatero-Rodríguez J, Corop CN, O’Kennedy RJ, Rudd PM, Saldiva R and Mondelli MU: Comprehensive N-Glycan profiling of avian immunoglobulin Y. PLoS One 11: e0159859, 2016.

32. Liu L: Antibody deaggregation and its impact on the pharmacokinetics and pharmacodynamics of monoclonal antibodies and Fc-fusion proteins. J Pharm Sci 104: 1866-1884, 2015.

33. Abbas AT, El-Kafrawy SA, Sahrob SS and Ahiar EIA: IgY antibodies for the immunomodulation of cytokines and therapy of respiratory infections. Hum Vaccin Immunother 15: 264-275, 2019.

34. Amro WA, Al-Qaisi W and Al-Razem F: Production and purification of IgY antibodies from chicken egg yolk. J Genet Eng Biotechnol 16: 99-103, 2018.

35. Hoffmann W, Lakki GS and Chalasani G: B cells, antibodies, and more. Clin J Am Soc Nephrol 11: 1347-1354, 2015.

36. Michael A, Meenatchisundaram S, Parameswari G, Subraj T, Selvakumaran R and Ramalingam S: Chicken egg yolk antibodies (IgY) as an alternative to mammalian antibodies. Indian J Sci Technol 3: 468-474, 2010.

37. Estmainnejad A, Abd-Elhachem B, Hosseini Nasab E and Sahmokori M: Production, purification, and evaluation of quail immunoglobulin Y against Salmonella typhimurium and Salmonella enteritidis. Mol Immunol 107: 79-83, 2019.

38. Ranjbar M, Behrouz F, Norouzi F and Mousavi Gargari SL: Anti-PcvrY IgY antibodies protect against Pseudomonas aeruginosa infection in both acute pneumonia and burn wound models. Mol Immunol 116: 98-105, 2019.

39. Thomsen K, Christophersen L, Jensen PO, Bjarnsholt T, Moser C and Hoiby N: Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial opsonization and augment the phagocytic activity of polymorphonuclear neutrophils. Hum Vaccin Immunother 12: 1690-1699, 2016.

40. Thomsen K, Christophersen L, Bjarnsholt T, Jensen PO, Moser C and Hoiby N: Anti-Pseudomonas aeruginosa IgY antibodies induce specific bacterial agglutination and internalization in human polymorphonuclear neutrophils. Infect Immun 83: 2686-2693, 2015.

41. Thirumalai D, Visaga Ambi S, Vieira-Pires RS, Xiaoying Z, Sekaran S and Krishnan U: Chicken egg yolk antibody (IgY) as diagnostics and therapies in parasitic infections - A review. Int J Biol Macromol 136: 755-763, 2019.

42. Runyan EPV, van Tilburg MF, Florean EOPT and Guedes MIF: Egg yolk antibodies (IgY) and their applications in human and veterinary health: A review. Int Immunopharmacol 73: 293-303, 2015.

43. Dunkelberger JR and Song WC: Complement and its role in innate and adaptive immune responses. Cell Res 20: 34-50, 2010.

44. Munhoz LS, Vargas GDA, Fischer G, Lima M, Esteves PA and Hübner SO: Avian IgY antibodies: Characteristics and applications in immunodiagnostic. Cienc Rural 44: 153-160, 2014.

45. Pauly D, Chacana PA, Calzado EG, Brembs B and Schade R: IgY technology: Extraction of antibodies from egg yolk by polyethylene glycol (PEG) precipitation. J Vis Exp 3081: 2011.

46. Ranolazki A, Zablocka A, Sosnowska A, Janusz M and Trziszka T: Immunomodulatory activity accompanying chicken egg yolk immunoglobulin Y. PLoS One 9(12): e112444, 2017.

47. Zhou X, Wang Y, Ahn DU and Cai Z: An easy and simple separation method for Fc and Fab fragments from chicken immunoglobulin Y. J Chromatogr A 1291: 2144-2156, 2010.

48. da Silva MC, Schilder R, Gava D, Souza CK, da Silva Vaz I Jr, Bastos AP and Venancio EJ: Production and application of anti-nuclear protein IgY antibodies for influenza A virus detection in swine. J Immunol Methods 461: 105-108, 2015.

49. Nagaraj S, Ramal S, Kingston J and Batra HV: Development of an influenza virus IgY sandwich ELISA for the detection of staphylococcal enterotoxin G (SEg2), an euc toxin. Int J Food Microbiol 237: 136-141, 2016.
Yolk IgG. J Immunol Methods 46: 63‑68, 1981.

50. Grzywa R, Lupicka-Stowik A, Walczak M, Idzi M, Bobrek K, Boivin S, Gawel A, Stefanaki T, Oleksyzyk J and Sienickzky M: Highly sensitive detection of cancer antigen 15-3 using novel immunoassay. ALTEX 31: 41-48, 2014.

51. Ferreira A Jr, Santos JP, Bassi PB, Bittar JFF and Bittar ER: IgY-technology applied to studies of toxoplasma gondii infection. In: Toxoplasmosis. IntechOpen, 2017. https://www.intechopen.com/books/toxoplasmosis/ig-y-technology-applied-to-studies-of-toxoplasma-gondii-infection. Accessed June 14, 2017.

52. Bayat M, Khayam MM, Razavi D and Hemati R: Development of IgY-based sandwich ELISA as a robust tool for rapid detection and discrimination of toxigenic Vibrio cholerae. Can J Infect Dis Med Microbiol 2018: e4032531, 2018.

53. Lupicka-Stowik A, Grzywa R, Leporowska E, Procyk D, Oleksyzyk J and Sienickzky M: Development and evaluation of an immunoglobulin Y-based ELISA for measuring prostatic specific antigen in human serum. Ann Lab Med 39: 373‑380, 2019.

54. Eisfeld AJ, Neumann G and Kawaoka Y: At the centre: Influenza A virus ribonucleoproteins. Nat Rev Microbiol 13: 28‑41, 2015.

55. Raja A, Stehmann C, Autelitano BJ, Vrckic AH, Hong CJ, Rice GE and Ilag LL: Protein depletion using IgY from chickens immunised with human protein cocktails. Prep Biochem Biotechnol 39: 221‑247, 2009.

56. Elm P: Advantages of multidimensional (Multi-D) chromatography using the NGC™ chromatography system over traditional extraction and chromatography Bulletin 6694. Bio-Rad Laboratories, Inc., Hercules, CA, 2016.

57. Casadevall A and Scharff MD: Return to the past: The case for anti‑sars coronavirus IgY from yolks of immunized SPF chickens. J Virol Methods 133: 112‑115, 2007.

58. Cheng VC, Lau SK, Yang CH, Poon PC and Yuen KY: Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev 20: 660‑694, 2007.

59. Gavi, The Vaccine Alliance: The latest in the COVID-19 vaccine race. https://www.gavi.org/vaccineswork/covid-19-vaccine-race. Accessed March 24, 2020.

60. Mail Online: FDA approves first US coronavirus treatment: Doctors across the US can now treat the sickest Americans with plasma from recovered patients. https://www.dailymail.co.uk/health/article-8147631/Can-blood-coronavirus-survivors-treat-plasma-recovered-patients.html. Accessed March 24, 2020.

61. Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Dobie P, Hulak M and Prabhu S: Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro. Procedia Vaccinol 6: 33-38, 2012.

62. Gallo CM, Honappa N, Hertel R, Eibl MM, Cornbleet PM and Scharff MD: Antibodies against swine influenza virus neutralize the pandemic influenza virus A/H1N1. Mol Med Rep 4: 209-214, 2011.

63. Sen W, Zhang H, Se D, Yang Y, Li Y and Zhu S: Preparation and characterization of egg yolk immunoglobulin Y specific to influenza B virus. AntiViral Res 93: 154‑159, 2012.

64. Yang YE, Wen J, Zhao S, Zhang K and Zhou Y: Prophylaxis and therapy of pandemic H1N1 virus infection using egg yolk antibody. J Virol Methods 206: 19‑26, 2014.

65. Walkagh MG, Webby RJ, Islam F, Walkden-Brown S, Emmoth C, Feinstein R and Gronvik KO: Cross-protection of chicken immunoglobulin Y antibodies against H5N1 and H1N1 viruses passively administered in mice. Clin Vaccine Immunol 18: 1083-1090, 2011.

66. Allendo PM, Bellido D, Chacana P and Wigdorovitz A: DusSantos MJ and Mozgovoj MV: Chicken egg yolk antibodies against bovine respiratory syncytial virus neutralize the virus in vitro. Procedia Vaccinol 6: 33-38, 2012.

67. Tisitoura E, Bikaki E, Bolaki M, Varvamidi E, Trachalaki A, Symvolakis EK, Spinadis DA and Antoniou KM: [Comment] Treatment strategies to fight the new coronavirus SARS-CoV-2: A challenge for a Rubik’s Cube solver. Exp Ther Med (In Press).

68. Docea AO, Tsatsakis A, Albulescu D, Cristea O, Zlatian O, Vincenti M, Moschos SA, Tsoukalas D, Goumenou M, Drakoulis N, et al.: A new threat from an old enemy: Re-emergence of coronavirus (Review). Int J Mol Med 45: 1631‑1643, 2020.

69. Lee W, Syed Atif A, Tan SC and Leow CH: Insights into the chicken IgY with emphasis on the generation and applications of chicken recombinant monoclonal antibodies. J Immunol Methods 447: 71‑85, 2020.

70. Spiller E, Braener J, Gruenke K, Seissmann H, Blank S and du Plessis D: Avian IgY antibodies and their recombinant equivalents in research, diagnostics and therapy. Biologicals 40: 313-322, 2012.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.